Fintech PR
Cboe Unveils New Brand for Exchange Technology Platform, Marking New Chapter in Technology Innovation and Growth
- Cboe’s exchange technology platform branded as Cboe TitaniumSM (Cboe TiSM)
- Titanium chosen as namesake to reflect Cboe Ti’s lightweight strength, durability and resilience
- New brand marks the milestone of Cboe’s final technology migrations to be completed in the first half of 2025
CHICAGO, Jan. 15, 2025 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), the world’s leading derivatives and securities exchange network, today unveiled a new brand identity for its exchange technology platform, signaling an exciting new chapter in Cboe’s ongoing evolution and deepening commitment to delivering best-in-class trading technology and innovation for market participants around the globe. The technology platform powering Cboe’s world-class exchange operations for trading options, futures and equities across its markets globally is now named Cboe TitaniumSM (Cboe TiSM).
“Cboe capped off another strong year of growth, delivering trading solutions and products to help customers around the globe navigate markets. Underpinning this success is Cboe’s leading-edge technology, which not only powers every aspect of our business and operations, but also helps to enable innovation across our markets, products, data and insights,” said Chris Isaacson, Chief Operating Officer at Cboe Global Markets. “Inspired by titanium’s exceptional durability and resilience, our new brand identity – Cboe Titanium, or Cboe Ti for short – aims to reflect the enduring strength, reliability and transformative power of our technology platform. As we look to the next chapter of Cboe’s growth, Cboe Ti will continue to deliver the world-class trading experience that our equities and derivatives customers globally have come to expect, helping to enable efficient price discovery, robust liquidity and opportunities for diverse trading strategies – all on a unified global technology platform.”
Cboe Ti (pronounced “T-I”, like the element symbol) powers Cboe’s options, equities and futures markets in the U.S., UK, Europe, Japan and Australia, with Cboe Canada expected to migrate to Cboe Ti on March 3, 2025. Cboe also plans to transition its cash-settled bitcoin and ether futures contracts, currently available for trading on the Cboe Digital Exchange, to the Cboe Futures Exchange (CFE) running on Cboe Ti in the second quarter of 2025, pending regulatory review. This will conclude a multi-year effort to bring all Cboe’s equities and derivatives markets across the globe onto a unified, globally consistent, yet locally optimized technology platform.
Using common protocols and features, Cboe’s unified technology platform is designed to offer customers an efficient, consistent experience regardless of where they are in the world. Meanwhile, the flexibility of Cboe Ti allows Cboe to locally optimize and customize the platform for the unique needs of any market or asset class. This enables enhanced consistency and scalability, allowing Cboe to build a feature or product once and then deploy it globally, bringing innovative products, features and data to new markets and customers at greater speed. This effort aligns with Cboe’s global strategy and commitment to expanding access to its markets, products, data and services to customers across the world.
Cboe expects to continue to invest in and scale its global technology infrastructure, operations and capabilities to meet market demand. Amid heightened volatility and record trading volumes in 2024, Cboe maintained 100% uptime across 25 of its 27 global platforms and achieved greater than 99.9% uptime across all 27 platforms. In U.S. options, where Cboe handled in 2024 approximately 100 billion quotes and orders a day across its four options exchanges, Cboe introduced a new access architecture to provide customers greater consistency for quoting and accessing liquidity. In equities, Cboe introduced Dedicated Cores, an optional service designed to help enhance consistency and improve overall performance for customers. Dedicated Cores reduced latency for customers who have purchased the service by 60% in the U.S. and has now been introduced in the UK and European Union, with plans to launch in Australia this month, pending regulatory approval.
Through powering trading operations, Cboe is committed to utilizing Cboe Ti to build a trusted global marketplace. To learn more, visit www.cboe.com/titanium.
About Cboe Global Markets
Cboe Global Markets (Cboe: CBOE), the world’s leading derivatives and securities exchange network, delivers cutting-edge trading, clearing and investment solutions to people around the world. Cboe provides trading solutions and products in multiple asset classes, including equities, derivatives and FX across North America, Europe and Asia Pacific. Above all, we are committed to building a trusted, inclusive global marketplace that enables people to pursue a sustainable financial future. To learn more about the Exchange for the World Stage, visit www.cboe.com.
|
Cboe Media Contacts |
Cboe Analyst Contact |
||||
|
Angela Tu  |
Tim Cave |
Kenneth Hill, CFA |
|||
|
+1-646-856-8734 |
+44 (0) 7593-506-719 |
+1-312-786-7559 |
|||
CBOE-C
CBOE-OE
Cboe® and Cboe Global Markets® are registered trademarks of Cboe Exchange, Inc. All other trademarks and service marks are the property of their respective owners.
Cautionary Statements Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as “may,” “might,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.
We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our dependence on and exposure to risk from third parties; global expansion of operations; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our growth and strategic acquisitions or alliances effectively; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, counterparty, investment, and default risks, associated with operating a European clearinghouse; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing potential conflicts between our regulatory responsibilities and our for-profit status; our ability to maintain BIDS Trading as an independently managed and operated trading venue, separate from and not integrated with our registered national securities exchanges; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the impacts of pandemics; the accuracy of our estimates and expectations; litigation risks and other liabilities; and risks relating to digital assets, including winding down the Cboe Digital spot market and transitioning digital asset futures contracts to CFE, operating a digital assets futures clearinghouse, cybercrime, changes in digital asset regulation, and fluctuations in digital asset prices. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2023 and other filings made from time to time with the SEC.
We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Logo – https://mma.prnewswire.com/media/622233/Cboe_GM_New_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cboe-unveils-new-brand-for-exchange-technology-platform-marking-new-chapter-in-technology-innovation-and-growth-302351119.html
LONDON and NEW YORK, Jan. 15, 2025 /PRNewswire/ — In March 2020, several of the largest institutional holders of sovereign bonds issued by Lebanon formed a group (the “Ad Hoc Group”) in response to the deteriorating financial and economic situation in the country and the government’s decision to default on its international bonds. The Ad Hoc Group’s stated objective from the outset has been to find a sustainable and equitable solution to Lebanon’s severe debt challenges. The Ad Hoc Group is supported by White & Case LLP as legal advisor.
The intervening years have witnessed a further decline of Lebanon’s political, economic and security situation, which has prevented any meaningful engagement with the Lebanese authorities. Despite the lack of progress to date, the Ad Hoc Group continues to provide a forum for coordination and communication among international bondholders, and remains prepared to engage constructively with the Lebanese authorities and other domestic and international stakeholders.
In this regard, the Ad Hoc Group is encouraged by the recent election of Joseph Aoun as President of Lebanon and nomination of Nawaf Salam as prime minister, and looks forward to the formation of a new government that will have the mandate to address the many challenges facing the country.
The Ad Hoc Group also takes note of last week’s statement of the Council of Ministers of Lebanon relating to the proposed suspension of Eurobond prescription periods until 9 March 2028, and confirms its willingness to discuss the implementation of the proposed suspension with the authorities and, at the appropriate time, to engage more broadly to find a resolution to the longstanding debt default.
Holders of Lebanon’s international bonds who wish to learn more about the Ad Hoc Group and its objectives, or discuss recent developments, may contact White & Case LLP by emailing [email protected].
View original content:https://www.prnewswire.co.uk/news-releases/statement-of-ad-hoc-lebanon-bondholder-group-302351961.html
Issued on behalf of Oncolytics Biotech Inc.
USA News Group News Commentary
VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ — As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI technologies, novel targeted therapies, and innovative cancer vaccines. With over 50 oncology drug approvals in 2024, including the first tumor-infiltrating lymphocyte cell therapy, this year holds great promise for precision medicine and immunotherapy. Amid growing expectations for an active year for biotech stocks in 2025, developers of new cancer therapies are already releasing important developments, with recent news coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Adaptive Biotechnologies Corporation (NASDAQ: ADPT), NeoGenomics, Inc. (NASDAQ: NEO), Elevation Oncology, Inc. (NASDAQ: ELEV), and ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC).
The article continued: Statista analysts project that the oncology drugs market will generate an estimated revenue of $208.9 billion in 2025. Meanwhile, Global Market Insights reports that the global oncology market, valued at approximately $320.3 billion in 2024, is expected to grow at a compound annual growth rate (CAGR) of 10.8% from 2025 to 2034, reaching $866.1 billion.
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany’s medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients.
Following a positive safety review by the independent Data Safety Monitoring Board (DSMB), which recommended continuation, the PEI’s approval allows Cohort 5 to progress to full enrollment. Early safety data will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium later this month, with initial efficacy results expected in the second half of the year.
“Pelareorep has the potential to meaningfully improve outcomes for patients with metastatic pancreatic cancer,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. “Encouraging tumor response rates observed in an earlier cohort of the GOBLET study underscore pelareorep’s promise in this disease. GOBLET Cohort 5 extends our evaluation by testing pelareorep with a different chemotherapy regimen, mFOLFIRINOX, which broadens the range of pancreatic cancer patients who may benefit from this innovative therapy. Positive results from this cohort may ultimately enable pelareorep to benefit the large majority of metastatic pancreatic patients for whom improved treatment options are badly needed.”
The Phase 1/2 GOBLET study is testing pelareorep, an oncolytic reovirus, in combination with other treatments for advanced gastrointestinal cancers, including pancreatic, colorectal, and anal cancers. Conducted at 17 centers in Germany, the study aims to evaluate response rates, safety, and biomarkers across multiple treatment arms, with promising cohorts advancing to further testing.
AIO is a non-profit organization that evolved from the medical oncology working group within the German Cancer Society (DKG). Dedicated to advancing science and research in medical oncology, AIO has grown into a prominent sponsor and study management company. Over the years, it has established a strong reputation both within Germany and on the international stage for its contributions to oncology research and study development.
Oncolytics Biotech’s work represents a significant step forward in the fight against metastatic pancreatic cancer, addressing a critical need for more effective treatment options in this aggressive disease. By leveraging the innovative potential of pelareorep in combination with established therapies, the company is paving the way for breakthroughs that could transform outcomes for patients and unlock value for investors.
CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the market include:
Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, recently announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers.
Adaptive’s clonoSEQ® is the first and only FDA-cleared test for detecting minimal residual disease (MRD) in lymphoid cancers, while NeoGenomics’ COMPASS® and CHART® offer comprehensive and personalized testing for complex blood cancers. By combining clonoSEQ with these advanced services, oncologists can develop tailored treatment plans, assess patient risk more accurately, and gain real-time insights into disease progression, enhancing care for blood cancer patients.
“As a leader in oncology testing with an extensive menu of precision oncology offerings, NeoGenomics is a natural partner for us,” said Chad Robins, CEO and Co-Founder of Adaptive Biotechnologies. “We are proud of this collaboration, which expands access to the valuable insights that clonoSEQ MRD results offer, ultimately helping more providers and patients benefit from knowing their MRD status.”
Under a new agreement, clinicians using NeoGenomics’ COMPASS diagnostic tool for blood cancers like multiple myeloma, B-ALL, CLL, and DLBCL can now include Adaptive Biotechnologies‘ clonoSEQ Clonality (ID) test at diagnosis to identify patient-specific DNA sequences for ongoing MRD (minimal residual disease) tracking. This integration allows seamless monitoring of disease burden throughout treatment using CHART, giving patients access to clonoSEQ insights and increasing eligibility for clinical trials that rely on MRD testing to guide therapy decisions. All clonoSEQ testing will be conducted at Adaptive’s specialized laboratory, ensuring accurate and consistent results.
Adaptive and NeoGenomics are preparing to implement the infrastructure for their partnership, with cross-promotional efforts expected to launch later this year, though financial terms remain undisclosed.
iBio, Inc. (NYSE-American: IBIO) an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., recently announced they’ve developed a breakthrough antibody targeting Activin E, a key protein linked to cardiometabolic disorders and obesity. This achievement demonstrates the strength of iBio’s platform in tackling challenging targets and advancing innovative therapies, with plans for rapid testing of this and other candidates in advanced disease models.
“Developing a functional antibody against Activin E, an achievement we believe to be an industry first, is a significant milestone for iBio,” said Martin Brenner, Ph.D., DVM, iCEO and Chief Scientific Officer of iBio. “This breakthrough strengthens our efforts to expand our therapeutics pipeline for the treatment of cardiometabolic disorders and obesity with innovative next-generation solutions.”
Elevation Oncology, Inc. (NASDAQ: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, recently announced program updates and upcoming milestones.
The company is advancing its pipeline with EO-3021, a potentially best-in-class antibody drug conjugate targeting Claudin 18.2 in advanced gastric/GEJ cancer, showing promising early results with a 42.8% overall response rate and a differentiated safety profile. The ongoing Phase 1 trial includes monotherapy and combination studies, with additional data expected in 2025 and 2026, while EO-1022, a HER3-targeting ADC for solid tumors, is progressing toward preclinical data release in 2025 and an IND filing in 2026.
“We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care,” said Joseph Ferra, President and CEO of Elevation Oncology. “As we enter 2025, we are honing our focus, leveraging the competitive anti-tumor activity and differentiated safety profile of EO-3021 to explore combination approaches in the first- and second-line settings.”
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, recently provided early Phase 1b combination data for ORIC-944, operational highlights for 2024, and anticipated upcoming milestones.
ORIC-944, a potent PRC2 inhibitor, has shown strong potential in treating metastatic castration-resistant prostate cancer (mCRPC), with deep and durable PSA responses and a favorable safety profile in early Phase 1b combination trials with apalutamide and darolutamide. Alongside advancements in ORIC-114 for NSCLC, ORIC’s 2024 milestones include promising clinical data, strategic collaborations with Johnson & Johnson and Bayer, and a robust cash position expected to support operations into late 2026, positioning the company for continued progress in oncology drug development.
“We made strong progress on multiple fronts in 2024, most notably with the initiation of multiple cohorts for ORIC-114 in NSCLC and ORIC-944 in mCRPC,” said Jacob M. Chacko, M.D., President and CEO of Oric. “We also forged three strategic collaborations with leading pharma partners, strengthened our leadership team to expand functional capabilities, and completed a $125 million PIPE financing, extending our cash runway into late 2026. These accomplishments position us well for 2025 and beyond, with seven anticipated data readouts over the next 18 months as we advance toward potentially initiating registrational studies for ORIC-114 in the second half of 2025 and for ORIC-944 in early 2026.”
CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.co.uk/news-releases/cutting-edge-cancer-therapies-lead-the-way-into-a-transformative-year-302351959.html
TIC Holding Schweiz AG, a Buy, Build and Technologize platform funded by Winterberg Investment X and managed by Winterberg Advisory GmbH, has acquired Metron Measurement SA based in Quartino, Switzerland
BAAR, Switzerland, Jan. 15, 2025 /PRNewswire/ — TIC Holding Schweiz has successfully completed the acquisition of Metron Measurement SA, an SCS-accredited laboratory specialized in calibrating measurement equipment in the field of Length, Force, Torque, Humidity, Pressure and Electrical quantities. Metron further offers active administration and handling of all the equipment of their customers and can even perform its services onsite.
TIC (Testing, Inspection, and Certification) services have been a focus for private equity groups for decades, particularly in Europe, driven by the sector’s non-cyclical nature and high levels of recurring revenues. Winterberg has explored this sector in Switzerland for more than three years before making its first acquisition and is currently pursuing further live transactions.
Lorenzo Tencati, Board Member at TIC Holding Schweiz and Partner in Winterberg, states: “After being in the M&A market in TIC in Switzerland for a long time, we have finally found the nucleus of our new platform. Metron has strong processes, and impressive growth and a highly motivated team to deliver its services at the highest standards, to the utmost satisfaction of its customers. We are also very happy that Alessandro Capone stays with us as CEO of Metron with a significant shareholding in TIC Holding Schweiz. Together with my partner Fabian Kroeher and the Winterberg team we are all up for an exciting journey to build a Swiss market leader in the next 5 to 7 years.”
Alessandro Capone, CEO of Metron Measurement, adds: “From the first meeting, we were convinced that Winterberg will be the right partner to take Metron to the next level. We have been growing our services and team every year and really look forward to now be able to strategically invest and grow by acquisition in addition. We are also extremely grateful to our first investor Brütsch Rüegger Tools and especially to its CEO Martin Wirth for their support and trust in us during the last 10 years of activity, since 2015. We want to ensure that our collaboration in the market remains at its current level and that we continue to best meet our customers’ needs.”
Martin Wirth, CEO of Brütsch Rüegger Tools, affirms: “We are pleased to transfer our stake in Metron to an investor poised to further develop the company strategically and to expand the group into new sectors beyond our current scope. We are confident they will successfully drive Metron’s continued growth and build on its strong momentum. Metron is and remains our reliable exclusive partner for testing and calibration services – a long-standing partnership that will continue. We will keep providing our customers with calibration services and process-integrated calibration solutions based on Metron’s comprehensive portfolio of expertise and solutions.”
About TIC Holding Schweiz AG
TIC Holding Schweiz aims at becoming one of Switzerland’s leading customer-centric groups with a strong commitment to quality, excellence and diversity. The holding is actively seeking to acquire small and medium enterprises in accredited Testing, Inspection and Certification Services, preferably in succession situations. By fostering an entrepreneurial culture and benefiting from latest technologies in all corporate functions, it aspires to generate above-market growth and returns. TIC Holding Schweiz is based in Baar, Switzerland and its first group company Metron Measurement SA is located in Quartino, Switzerland.
About Winterberg Advisory GmbH and Winterberg Group AG
Based in Gruenwald, Germany, Winterberg Advisory GmbH manages private equity investment funds, mainly concentrating on small- and mid-cap successions, creating Buy, Build and Technologize platforms such as TIC Holding Schweiz AG and Healthcare Holding Schweiz AG. Winterberg Group AG, located in Zug, Switzerland, is an independent family office that invests in private equity, along with selective ventures in real estate and other asset classes.
Note to Editors: Please credit Winterberg Group for all references to provided quotes and information.
For further information about TIC Holding Schweiz AG, please visit www.tic-holding.ch.
For further information about Metron Measurement SA, please visit www.metron-labo.ch.
For further information about Winterberg Advisory GmbH and Winterberg Group AG, please visit www.winterberg.group. Winterberg’s Swiss healthcare platform Healthcare Holding Schweiz AG can be found under www.healthcare-holding.ch.
This press release is prepared and distributed by Winterberg Advisory GmbH on behalf of TIC Holding Schweiz AG.
Photo: https://mma.prnewswire.com/media/2598759/TIC_Holding_Schweiz_AG.jpg
For media inquiries, please contact:
Kaja Funke
[email protected]
+4915118859825
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tic-holding-schweiz–winterberg-acquire-metron-measurement-sa-302351890.html
-
Fintech PR5 days agoHTX 2025 Outlook: Five Sectors to Look Forward to, and How Trump’s Policy Will Affect Crypto Industry
-
Fintech PR5 days agoNovo Holdings invests in $200M Series A for Windward Bio launch to advance long-acting treatments for asthma and COPD
-
Fintech PR5 days agoAZZURRI GROUP LAUNCHES ITS 2024 SUSTAINABLE DINING REPORT AND ACHIEVES FURTHER REDCUTIONS IN CARBON EMISSIONS
-
Fintech PR5 days agoFintech nsave launches investment platform, offering people from distressed economies protection from inflation with compliant and safe investments abroad
-
Fintech PR5 days agoAmrop, a Leading Global Executive Search and Leadership Consulting Firm, Announces New Office in Japan
-
Fintech PR5 days ago2024 Marks Breakout Year for China’s ETF Market with Unprecedented Growth
-
Fintech PR5 days agoStockGro Partners with GIIS Dubai to Transform Youth Financial Literacy in the UAE
-
Fintech20 hours agoFintech Pulse: Your Daily Industry Brief (Float Financial, Alza Fintech, Thrive Capital, Stripe, Unzer, Agora Data)